# US 2015/0105350 A1 · Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105350 A1
- Document ID: US20150105350A1
- Status: Published application
- Kind: A1
- Application number: 14/376,116
- Filed: 2013-02-01
- Published: 2015-04-16
- Earliest claimed: 2012-02-03
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Srinivasan Ramanathan
- Web page: https://patentgrep.com/patent/US20150105350A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/35: having six-membered rings with one oxygen as the only ring hetero atom
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The use of the hemifumarate form of {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and elvitegravir, and the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and darunavir, are disclosed.

## Claims

### Claim 1

A composition comprising: cobicistat, or a pharmaceutically acceptable salt thereof; and tenofovir alafenamide hemifumarate.

### Claim 2 (depends on 1)

The composition of claim 1 comprising: 50-500 mg of cobicistat, or a pharmaceutically acceptable salt thereof; and 3-40 mg of tenofovir alafenamide hemifumarate.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier or diluent.

### Claim 4 (depends on 1)

A method of treating a viral infection in a human comprising administering a composition of claim 1 to the human.

### Claim 5

A method of treating a viral infection in a human comprising coadministering cobicistat, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide hemifumarate, to the human.

### Claim 6

A method of inhibiting activity of a retroviral reverse transcriptase comprising coadministering cobicistat, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide hemifumarate.

### Claim 7 (depends on 6)

The method of claim 6, wherein the coadministering of cobicistat, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide hemifumarate, is in a human.

### Claim at position 8

8-11. (canceled)

### Claim 12 (depends on 1)

A method of boosting an anti-viral effect of tenofovir alafenamide hemifumarate in a human comprising administering a composition of claim 1 to the human.

### Claim 13

A method of boosting an anti-viral effect of tenofovir alafenamide hemifumarate in a human comprising coadministering cobicistat, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide hemifumarate to the human.

### Claim 14 (depends on 13)

The method of claim 13, wherein 50-500 mg of cobicistat, or a pharmaceutically acceptable salt thereof, is coadministered with 3-40 mg of tenofovir alafenamide hemifumarate.

### Claim 15 (depends on 1)

A method of inhibiting Pgp-mediated intestinal secretion of tenofovir alafenamide hemifumarate in a human comprising administering a composition of claim 1 to the human.

### Claim 16

A method of inhibiting Pgp-mediated intestinal secretion of tenofovir alafenamide hemifumarate in a human by coadministration of cobicistat, or a pharmaceutically acceptable salt thereof, and tenofovir alafenamide hemifumarate.

### Claim 17 (depends on 16)

The method of claim 16, wherein 50-500 mg of cobicistat, or a pharmaceutically acceptable salt thereof, is coadministered with 3-40 mg of tenofovir alafenamide hemifumarate.

### Claim 18 (depends on 5)

The method of claim 5, wherein the viral infection is human immunodeficiency virus (HIV) or Hepatitis B virus (HBV).

### Claim 19

(canceled)

### Claim 20 (depends on 13)

The method of claim 13, wherein the virus is human immunodeficiency virus (HIV) or Hepatitis B virus (HBV).

### Claim 21

A composition comprising: (a) tenofovir alafenamide hemifumarate; (b) cobicistat, or a pharmaceutically acceptable salt thereof; (c) emtricitabine; and (d) elvitegravir.

### Claim 22

A composition comprising: (a) 3-40 mg tenofovir alafenamide hemifumarate; (b) 50-500 mg cobicistat, or a pharmaceutically acceptable salt thereof; (c) 50-500 mg emtricitabine; and (d) 50-500 mg elvitegravir.

### Claim 23 (depends on 21)

A method of treating a viral infection in a human comprising administering a composition of claim 21 to the human.

### Claim 24

A method of treating a viral infection in a human comprising coadministering (a) tenofovir alafenamide hemifumarate; (b) cobicistat, or a pharmaceutically acceptable salt thereof; (c) emtricitabine; and (d) elvitegravir to the human.

### Claim 25 (depends on 24)

The method of claim 24 comprising coadministering (a) 3-40 mg tenofovir alafenamide hemifumarate; (b) 50-500 mg cobicistat, or a pharmaceutically acceptable salt thereof; (c) 50-500 mg emtricitabine; and (d) 50-500 mg elvitegravir to the human.

### Claim at position 23

26-30. (canceled)

### Claim 31 (depends on 24)

The method of claim 24, wherein the viral infection is human immunodeficiency virus (HIV) or Hepatitis B virus (HBV).

### Claim 32

(canceled)
